乳腺癌中的代谢重编程:驱动进展,耐药性和新兴治疗方法的途径
Pankaj Garg1, Gargi Singhal2, David Horne3
1Department of Chemistry, GLA University, Mathura, Uttar Pradesh 281406, India.
Biochimica et biophysica acta. Reviews on cancer
|July 23, 2025
概括
乳腺癌 (BC) 在各个亚型中表现出多样化的代谢特征,推动了其进展和抵抗力. 针对这些代谢依赖,为改善乳腺癌治疗结果提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 分子生物学分子生物学
背景情况:
- 乳腺癌 (BC) 是女性癌症相关死亡的主要原因,其特点是显著的分子异质性.
- 异常的细胞代谢是癌症的公认标志,驱动瘤进展,治疗耐药性和BC的转移.
- 不同的BC亚型,包括激素受体阳性,HER2阳性和三阴性BC亚型,表现出不同的代谢概况.
研究的目的:
- 分析各种乳腺癌亚型中的代谢重编程.
- 阐明糖解,脂质新陈代谢,氨基酸新陈代谢和线粒体生物生成如何促进BC增殖和生存.
- 突出代谢副产品在瘤微环境中的作用,免疫抑制和瘤适应营养贫乏,缺氧条件.
主要方法:
- 关于乳腺癌代谢的当前文献的综述.
- 分析不同BC分子亚型所使用的代谢途径.
- 在瘤微环境中的代谢标志的插图.
主要成果:
- BC亚型利用不同的代谢途径 (糖解,脂质,氨基酸代谢,线粒体生物发生) 进行生长.
- 重编程的代谢途径产生了对免疫抑制和在具有挑战性的瘤微环境中生存至关重要的副产品.
- 新兴的抗癌药物针对这些特定的代谢依赖.
结论:
- 了解BC代谢重编程是开发有效疗法的关键.
- 准代谢漏洞是一个有前途的战略,用于特定亚型的乳腺癌治疗.
- 本综述将基础科学和临床观点结合起来,以指导BC的未来代谢干预.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.5K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
